ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Astellas Pharma, Inc.

Business Summary

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2022 JPYUSD
Revenue1,296.16B11,534.50M
Gross Profit1,014.87B9,031.29M
Operating income220,021M1,957.95M
Income before tax156,397M1,391.77M
Net income124,086M1,104.23M
EBITDA299,705M2,667.06M
Diluted EPS67.050.59
Dividends Per Share500.44
Total Assets2,332.39B19,216.43M
Total liabilities872,086M7,185.05M
Total equity1,460.30B12,031.37M
Operating cash flow258,160M2,297.35M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 1,300.31B 1,306.34B 1,300.84B 1,249.52B 1,296.16B
Gross Profit 970,228M 979,086M 1,002.94B 979,702M 1,014.87B
Operating income 271,241M 280,141M 279,419M 250,897M 220,021M
Income before tax 218,113M 248,967M 247,010M 144,846M 156,397M
Net income 164,679M 222,265M 195,411M 120,589M 124,086M
EBITDA 336,104M 343,599M 345,815M 323,549M 299,705M
Diluted EPS 81.02 114.94 104.07 64.89 67.05
Dividends Per Share 36 38 40 42 50
Total Assets 1,858.20B 1,897.64B 2,315.16B 2,273.62B 2,332.39B
Total liabilities 589,916M 639,252M 1,026.00B 887,514M 872,086M
Total equity 1,268.28B 1,258.39B 1,289.16B 1,386.11B 1,460.30B
Operating cash flow 314,463M 261,428M 224,060M 307,880M 258,160M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 11,732.27M 11,780.07M 11,964.43M 11,781.61M 11,534.50M
Gross Profit 8,754.00M 8,828.97M 9,224.49M 9,237.46M 9,031.29M
Operating income 2,447.30M 2,526.19M 2,569.94M 2,365.67M 1,957.95M
Income before tax 1,967.95M 2,245.07M 2,271.86M 1,365.73M 1,391.77M
Net income 1,485.83M 2,004.28M 1,797.28M 1,137.01M 1,104.23M
EBITDA 3,032.54M 3,098.42M 3,180.61M 3,050.69M 2,667.06M
Diluted EPS 0.73 1.03 0.95 0.61 0.59
Dividends Per Share 0.32 0.34 0.36 0.39 0.44
Total Assets 17,472.54M 17,144.58M 21,445.68M 20,575.81M 19,216.43M
Total liabilities 5,546.92M 5,775.41M 9,503.95M 8,031.80M 7,185.05M
Total equity 11,925.61M 11,369.16M 11,941.71M 12,544.02M 12,031.37M
Operating cash flow 2,837.28M 2,357.44M 2,060.78M 2,902.95M 2,297.35M

Valuation Measures

Mar 2022
PER28.48
ROA5.38%
ROE8.71%
Operating margin16.97%
Profit margin9.57%

Key executives

  • Chairman, President & Chief Executive Officer: Kenji Yasukawa
  • Chief Financial Officer: Minoru Kikuoka
  • Chief Scientific Officer: Yoshitsugu Shitaka
  • Head-Business Administration & Compliance: Fumiaki Sakurai
  • VP, Head-Oncology Therapeutic Area in Mktg Strat: Peter Sandor

Shareholders

  • Nomura Asset Management Co., Ltd. (6.2%)
  • Wellington Management Co. LLP (4.2%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.4%)
  • Nikko Asset Management Co., Ltd. (3.3%)
  • Daiwa Asset Management Co. Ltd. (2.8%)
  • Nippon Life Insurance Co. (2.8%)
  • The Vanguard Group, Inc. (2.6%)
  • BlackRock Fund Advisors (1.8%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (1.5%)
  • Norges Bank Investment Management (1.5%)

Contact Details

  • Website:http://www.astellas.com
  • Address: 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411, Japan
  • Phone: +81.3.3244.3000

Related Companies

  • Astellas Pharma, Inc. /5 Legacy Products/
  • Astellas Pharma, Inc. /Milrila Injection Product/
  • OSI Pharmaceuticals, LLC
  • Representative Office of Astellas Pharma Singapore
  • Astellas Pharma Malaysia Sdn. Bhd.
  • Astellas Green Supply, Inc.
  • Xyphos Biosciences, Inc.
  • Iota Biosciences, Inc.
  • Astellas Pharma, Inc. /Agensys Research Facilities/
  • Astellas Pharma, Inc. /16 Long Listed Products/
  • Astellas Farma Colombia
  • Astellas Pharma Director Incentive Plan
  • Quethera Ltd.
  • PT Astellas Pharma Indonesia
  • Astellas Pharma ZAO
  • Astellas Pharma Hong Kong Co., Ltd.
  • Astellas Pharma India Pvt Ltd.
  • Astellas Pharma (Thailand) Co., Ltd.
  • Astellas Pharma Australia Pty Ltd.
  • Astellas Pharma Singapore Pte Ltd.
  • Astellas Pharma Tech Co., Ltd.
  • Astellas Gene Therapies, Inc.
  • Mitobridge, Inc.
  • Astellas Pharma China, Inc.
  • Perseid Therapeutics LLC
  • GPDC Partnership
  • Astellas Pharma Philippines, Inc.
  • Astellas Pharma Co. Ltd.
  • Astellas Pharma Canada, Inc.
  • Fujisawa Taiwan Co. Ltd.

Competitors

  • AstraZeneca PLC
  • JW Holdings Corporation
  • Lantern Pharma, Inc.
  • Alembic Pharmaceuticals Limited
  • AbClon, Inc.
  • Ipsen SA
  • Eledon Pharmaceuticals, Inc.
  • DexTech Medical AB
  • Poseida Therapeutics, Inc.
  • OSE Immunotherapeutics SA
  • ADC Therapeutics Ltd
  • MedPacto, Inc.
  • Bicycle Therapeutics Plc Sponsored ADR
  • Golden Biotechnology Corp.
  • Agenus Inc.
  • DongKoo Bio & Pharm Co. Ltd.
  • LegoChem Biosciences, Inc.
  • Akebia Therapeutics, Inc.
  • Cullinan Oncology, Inc.
  • Editas Medicine, Inc.
  • ERYTech Pharma SA
  • Keros Therapeutics, Inc.
  • Kura Oncology, Inc.
  • Synthetic Biologics, Inc.
  • Foresee Pharmaceuticals Co., Ltd.
  • GlycoMimetics, Inc.
  • LogicBio Therapeutics, Inc.
  • Aptevo Therapeutics Inc
  • Cyclerion Therapeutics,Inc.
  • ImmunoGen, Inc.
Last Updated on 10 Aug, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more